Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by American International Group Inc.

American International Group Inc. trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,300 shares of the specialty pharmaceutical company’s stock after selling 3,917 shares during the period. American International Group Inc. owned approximately 0.14% of Jazz Pharmaceuticals worth $10,492,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after buying an additional 29,960 shares in the last quarter. FMR LLC grew its position in Jazz Pharmaceuticals by 8.1% in the third quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock worth $172,560,000 after acquiring an additional 100,349 shares in the last quarter. Ameriprise Financial Inc. grew its position in Jazz Pharmaceuticals by 4.6% in the third quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock worth $168,222,000 after acquiring an additional 57,717 shares in the last quarter. Polaris Capital Management LLC increased its stake in shares of Jazz Pharmaceuticals by 2.2% during the 4th quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock worth $155,898,000 after purchasing an additional 27,100 shares during the last quarter. Finally, Pacer Advisors Inc. raised its holdings in shares of Jazz Pharmaceuticals by 28.1% during the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after purchasing an additional 224,865 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JAZZ has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. Barclays reduced their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. Royal Bank of Canada reiterated an “outperform” rating and set a $195.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Finally, Stifel Nicolaus boosted their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $190.92.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the sale, the executive vice president now directly owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $114.53 on Tuesday. The firm has a market capitalization of $7.22 billion, a PE ratio of 23.61, a PEG ratio of 1.73 and a beta of 0.62. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. Jazz Pharmaceuticals plc has a 1-year low of $103.01 and a 1-year high of $146.70. The business’s 50 day moving average is $109.31 and its 200-day moving average is $117.47.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.